[india-drug] Illegal promotion of Letrozole in India

[owner-india-drug@healthnet.org]

(Copied form Edrug. Thanks?SS)

Illegal promotion of Letrozole in India
----------------------------------------------------------

Anti-cancer drug being illegally promoted as "Infertlity Cure" in India

An expensive anti-cancer agent letrozole is being promoted illegally
and unethically to gynaecologists for "improving" fertility in females
in India by Mumbai-based Sun Pharmaceuticals, Delhi-based Dabur India
Ltd., Chennai-based Fourrts Laboratories Ltd. And Hyderabad-based Natco
Pharma Ltd. The drug is approved for the treatment of breast cancer
only by the Drugs Controller General, India (DCGI).

Promoting medicines for unapproved uses is unlawful in India. Such
drugs are deemed to be misbranded under the provisions of Drugs and
Cosmetics Act and manufacturers are punishable with fine and
imprisonment ranging from one to two years. 

Curiously enough two companies, Sun Pharmaceuticals and Dabur are
marketing the same drug under two different brand names each. According
to drug experts this is strange and is apparently meant to corner a
bigger pie of the same drug's market through multiple branding.

Responding to the allegation of illegal promotion, Sun Pharmaceuticals
has acknowledged that its "marketing people might have gone overboard"
in promoting the drug without DCGI permission. However investigations
reveal that Sun Pharma circulated thousands of promotional leaflets
throughout India under the title "Letroz - the New Perspective in
Ovulation Induction." Letroz is Sun
Pharmaceutical's brand name of letrozole.

Furthermore, scores of seminars were held all over India where
gynaecologists were invited to listen to lectures by Company- sponsored
fertility experts endorsing the use of letrozole in infertile women.
The seminars were continuing right into early September. 

Letrozole is embryotoxic and fetotoxic as per the literature issued by
the original discoverer, Novartis, and endorsed by drug regulators from
the United States, Britain and Australia. Even in India, the drug's
monograph as approved by the DCGI acknowledges these serious side
effects. Letrozole is also teratogenic and can cause malformation of
babies. Even at minuscule doses of 0.03mg/kg
 (about 1/10th of normal human per kg dose) the drug can lead to foetal
domed head and cervical vertebral fusion.

Administering a drug for unapproved indications can lead to legal
action both against the prescribers and the producers under various
laws including Consumer Protection Act.

Dr. Chandra M. Gulhati
Editor, MIMS INDIA
503 Mansarovar
90 Nehru Place
New Delhi, India





________________________________________________________________________
Yahoo! India Matrimony: Find your partner online.
Go to http://yahoo.shaadi.com

Access Essential Drugs Monitor #32 at http://www.who.int/medicines/mon/mon32.shtml

The INDIA-DRUG discussion group is a partnership between SATELLIFE
(www.healthnet.org), WHO Essential Drugs and Medicines Policy
(www.who.ch), and the Delhi Society for the Promotion of the
Rational Use of Drugs (DSPRUD) in India.

To send a message to india-drug, write to: india-drug@healthnet.org
To subscribe or unsubscribe, write to: majordomo@healthnet.org
in the body of the message type: subscribe india-drug OR unsubscribe india-drug
To contact a person, send a message to: india-drug-help@healthnet.org